BioMedNewsBreaks – HealthLynked Corp. Names Jeremy Daniel as Chief Financial Officer

HealthLynked (OTCQB: HLYK) a provider of healthcare technology solutions, has appointed Jeremy Daniel as its new Chief Financial Officer, effective immediately. With over 20 years of experience in healthcare, biotechnology, and finance, Daniel brings expertise in financial management, strategic planning, and organizational growth. Previously CFO at Innoveren Scientific, he has a strong track record in fundraising, mergers, and acquisitions, having raised over $100 million in funding. CEO Michael Dent, M.D., highlighted Daniel’s alignment with HealthLynked’s mission to innovate and expand its healthcare technology solutions. Daniel, a CPA and Xavier University MBA graduate, expressed enthusiasm for advancing the company’s financial strategies and enhancing healthcare connectivity.

To view the full press release, visit https://ibn.fm/tKrLK

About HealthLynked Corp.

HealthLynked Corp. is committed to improving global healthcare by facilitating the efficient exchange of medical information between patients and providers. The company’s network empowers members to actively manage their healthcare through a centralized and secure platform. For more information about HealthLynked Corp., please visit www.healthlynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HealthLynked are available in the company’s newsroom at https://IBN.fm/HLYK

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission 

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received…

19 hours ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology

Oncotelic Therapeutics (OTCQB: OTLC) today announced its inclusion in an editorial published by NetworkNewsWire (“NNW”),…

20 hours ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its RADR(R) AI platform to transform…

21 hours ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Partners with HeartNexus to Deliver 24/7 Remote Cardiology Services and Real-Time ECG Interpretation

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights,…

22 hours ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl 

Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as…

2 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Featured in Channelchek Report Highlighting AVERSA Fentanyl Progress

Nutriband (NASDAQ: NTRB), a pharmaceutical company developing transdermal drug delivery technologies, was featured in a…

5 days ago